# Everolimus

## Afinitor 5mg

| TAH Drug Code      | [OAFI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OAFI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | AFINITOR in combination with exemestane is indicated for the treatment of postmenopausal women with hormone receptor-positive， HER2-negative， advanced breast cancer that has recurred or progressed after prior treatment with letrozole or anastrozole. AFINITOR is indicated for the treatment of progressive， unresectable， or metastatic well-differentiated or moderately-differentiated pancreatic neuroendocrine tumors in adult patients. AFINITOR is indicated for the treatment of unresectable， locally advanced， or metastatic progressive， well-differentiated non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or pulmonary origin in adult patients. AFINITOR is indicated for the treatment of advanced renal cell carcinoma in patients who have not responded to VEGF-targeted therapy. |
| Dosing             | [Advanced Breast cancer， hormone receptor-positive， HER2-negative; Advanced Neuroendocrine tumors (GI， lung， or pancreatic origin); Advanced Renal cell cancer (RCC)] 10 mg orally once daily， continue treatment until disease progression or unacceptable toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypersensitivity to everolimus or other rapamycin derivatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Stomatitis， infections， rash， fatigue， diarrhea， decreased appetite， hyperglycemia， dyspnea， pneumonitis， hypercholesterolemia， increased AST & ALT， anemia， leukopenia， thrombocytopenia， lymphopenia， hypertriglyceridemia， decreased K.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Moderate Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/everolimus-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

